详情页 - 昆明医科大学第一附属医院知识库

当前位置：首页 > 详情页

Helicobacter pylori promotes gastric cancer progression by upregulating semaphorin 5A expression via ERK/MMP9 signaling.

171| 导出 | 链接全文 |

文献详情

资源类型：

WOS体系：

Pubmed体系：

收录情况： ◇ SCIE

作者：

机构： [1]Department of Pathology, The First Affiliated Hospital of Kunming Medical University, No. 295 Xichang Road, Kunming, Yunnan Province 650100, P.R. China [2]Department of Pathology, The Maternity and Child Care Hospital, Qujing, Yunnan, P.R. China [3]Department of Pathology, Yan An Hospital, Kunming, Yunnan, P.R. China

出处：

DOI：

ISSN：

摘要：

Helicobacter pylori (H. pylori) infection is the strongest risk factor for the occurrence and development of gastric carcinoma. However, the molecular mechanism underlying H. pylori-induced pathogenesis has not yet been fully characterized. Here, we explored whether H. pylori upregulates semaphorin 5A to promote gastric cancer progression via the extracellular regulated protein kinases/matrix metalloproteinase (ERK/MMP9) signaling pathway. In this study, H. pylori upregulated semaphorin 5A expression in vitro and in vivo. Using the human gastric carcinoma cell lines SGC7901, SGC7901-siScrambled, and SGC7901-siSema 5A, our studies showed that H. pylori increased the proliferation, growth, migration, and invasiveness of gastric cancer cells via its effects on semaphorin 5A and that H. pylori increased the expression of MMP9 in gastric cancer cells via the semaphorin 5A-mediated ERK signaling pathway. Further analysis revealed that the ERK inhibitor PD98059 and MMP9 antibody (Ab) attenuated H. pylori-induced gastric cancer cell invasion and metastasis in vitro through a semaphorin 5A-dependent mechanism. In conclusion, H. pylori could promote gastric cancer progression in a semaphorin 5A-dependent manner via the ERK/MMP9 signaling pathway. Semaphorin 5A and its related signaling molecules potentially represent latent targets for H. pylori-related gastric cancer therapy.© 2021 The Author(s).

基金：

语种：

被引次数：

WOS：

PubmedID：

中科院(CAS)分区：

出版当年[2022]版：

大类 | 2 区医学

小类 | 2 区医学：研究与实验 3 区肿瘤学

最新[2023]版：

大类 | 2 区医学

小类 | 2 区医学：研究与实验 3 区肿瘤学

JCR分区：

出版当年[2021]版：

Q2 MEDICINE, RESEARCH & EXPERIMENTAL Q2 ONCOLOGY

最新[2023]版：

Q1 ONCOLOGY Q1 MEDICINE, RESEARCH & EXPERIMENTAL

影响因子： 5.3 最新[2023版] 5.2 最新五年平均 6.311 出版当年[2021版] 6.71 出版当年五年平均 7.2 出版前一年[2020版] 5.7 出版后一年[2022版]

第一作者：

第一作者机构： [1]Department of Pathology, The First Affiliated Hospital of Kunming Medical University, No. 295 Xichang Road, Kunming, Yunnan Province 650100, P.R. China [*1]Department of Pathology, The First Affiliated Hospital of Kunming Medical University, No. 295 Xichang Road, Kunming, Yunnan Province 650100, P.R. China.

共同第一作者：

通讯作者：

通讯机构： [1]Department of Pathology, The First Affiliated Hospital of Kunming Medical University, No. 295 Xichang Road, Kunming, Yunnan Province 650100, P.R. China [3]Department of Pathology, Yan An Hospital, Kunming, Yunnan, P.R. China [*1]Department of Pathology, The First Affiliated Hospital of Kunming Medical University, No. 295 Xichang Road, Kunming, Yunnan Province 650100, P.R. China. [*2]Department of Pathology, Yan An Hospital, Kunming, Yunnan, P.R. China. [*3]Department of Pathology, The First Affiliated Hospital of Kunming Medical University, No. 295 Xichang Road, Kunming, Yunnan Province 650100, P.R. China.

推荐引用方式(GB/T 7714)：

APA：

MLA：